Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
Krystal Biotech (NASDAQ: KRYS) announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference on October 4-5, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference on October 4-5, 2021. CEO Krish Krishnan will engage in a fireside chat, while SVP Whitney Ijem will join a panel on non-traditional viral vectors on October 5. The fireside chat is scheduled for 11:00 AM ET, following the panel at 9:30 AM ET. Interested parties can access live webcasts through the provided links, with replays available for 30 days post-event. Krystal Biotech focuses on developing therapies for rare diseases using its innovative gene therapy platform.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +0.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021. Krish Krishnan, Chairman and CEO at Krystal Biotech, will participate in a fireside chat, and Whitney Ijem, SVP, Strategy & Business Development, will join a panel discussion on the utility of non-traditional viral vectors.
Details for the conference are as follows:
| Chardan Virtual 5th Annual Genetic Medicines Conference | |
| Panel details: | Gene Therapy: The Utility of Viral Vectors Non-Traditional Panel Tuesday, October 5 at 9:30am ET |
| Fireside chat: | Tuesday, October 5 at 11:00am ET |
| Fireside Webcast link: | https://wsw.com/webcast/chard9/krys/1895635; |
To access live webcasts of Krystal’s presentation, please visit the Events & Presentations website page. Replays of webcasts will be available for 30 days following the event.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit http://www.krystalbio.com.
| CONTACTS: | |
| Investors: Whitney Ijem Krystal Biotech wijem@krystalbio.com | Media: Mary Coyle TellMed Strategies mary.coyle@tmstrat.com |
Source: Krystal Biotech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.